Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2019

View Archived Issues

miR-183-5p/Erbin signaling pathway regulates proliferation and differentiation of AML cells

Human alpha-galactosidase mRNA therapy for the treatment of Fabry disease: preclinical results

ADC targets wild-type and mutated ALK

Synthetic lethal strategy for pancreatic cancer

An orchestrated nuclear phosphoinositide kinase complex regulates p53 stabilization

Obesity, insulin resistance bring on blood-brain barrier breakdown

Enrollment ongoing in phase II study of recombinant subunit tuberculosis vaccine GamTBvac

Lutris Pharma initiates phase I study of LUT-014 in patients with mCRC

Phase III ALLEVIATE study of reproxalap meets the primary and key secondary endpoint

New mutations found in a case of idiopathic hypogonadotropic hypogonadism

ONO-ST-468 suppresses excessive GH secretion in GHRH/arginine-induced GH hypersecretion model

FDA clears Selvita's IND application to conduct phase I study of SEL-120

NSD2 is a novel biomarker and potential epigenetic target for retinoblastoma

Topline data presented from phase II advanced liver cancer study of namodenoson

ALK-4290 demonstrates safety and improvement in BCVA score in patients with nAMD

Shanghai Meizer Pharmaceuticals patents ALK kinase receptor inhibitors

Roche discloses compounds binding E3 ubiquitin-protein ligase

Lysophosphatidic acid receptor 1 antagonists identified at Lilly

Amgen describes new Mcl-1 inhibitors

AcuraStem patents 1-phosphatidylinositol 3-phosphate 5-kinase inhibitors

Rosuzet approved in Japan for hypercholesterolemia and familial hypercholesterolemia

Progesterone found to predict prognosis of adrenocortical carcinoma

FDA approves Mayzent for relapsing forms of MS

Boronated analogues of pleuromutilins show promise for filarial infections in vivo

Revcovi approved in Japan for ADA deficiency

Phase II trial of Triplex for CMV complications in HSCT recipients meets primary endpoint

IMV reports preliminary phase II data for DPX-Survivac in ovarian cancer

NBE-Therapeutics describes antibody product targeting ROR1

AnGes obtains conditional approval in Japan for HGF plasmid in critical limb ischemia

Foscavir approved in Japan to treat HHV-6 encephalitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...